Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer Treatment

Collaborative and Seamless Care in Oncology : a Study in Primary Care to Measure and Reinforce Safety and Adherence to Oral Cancer Treatment

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01370980

Enrollment

Registered

2011-06-10

Start date

2010-07-01

Completion date

2014-09-01

Last updated

2026-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

Medication Adherence, Patient Compliance, Patient Acceptance of Health Care, Administration, Oral, Cancer, Letrozol, Exemestan, Imatinib, Sunitinib, Nilotinib, Everolimus, Deferasirox

Brief summary

The purpose of this study is to implement a support interdisciplinary program(oncologists, pharmacists, physicians, nurses, leagues against cancer) of medication adherence to oral oncology treatments. The aim is to ensure continuity of care between professionals,effectiveness of treatment and patient safety.

Detailed description

80 patients will be included in swiss-romande hospitals and private oncologists and followed by thirty study pharmacies. Each refusal and drop-out will be documented. Follow-up duration is 48 weeks, with a motivational interviewing at least every three months. Patient adherence will be assessed electronically by MEMS (Medication Event Monitoring System).

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* 18 years and older * Treated for a cancer with oral medication (letrozol, exemestan,imatinib, sunitinib, nilotinib, everolimus, deferasirox) * French speaking

Exclusion criteria

\- None

Design outcomes

Primary

Measure	Time frame	Description
Change in Medication adherence	3 months, 6 months, 9 months, 12 months	MEMS data, completed by informations given in motivational interviewing

Secondary

Measure	Time frame	Description
Program implementation	1 year	Evaluating the implementation of the program in pharmacies
Oncologists, nurses, pharmacists and patients satisfaction	1 year	By questionnaire and interviews
Effect of Adverse Drug Reaction (ADR) on medication adherence	1 year	By MEMS data and motivational interviewing informations
Change in Adverse Drug Reaction (ADR)	3 months, 6 months, 9 months, 12 months	To evaluate the frequency and severity of ADR and the pharmacist's contribution to their management. Data from motivational interviewing.

Countries

Switzerland

Contacts

STUDY_CHAIRBugnon Olivier, Professor

Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland

STUDY_CHAIRLüthi François, Dr

Clinique Bois-Cerf, Lausanne

PRINCIPAL_INVESTIGATORSchneider Marie-Paule, PhD

Policlinique Medicale Universitaire

PRINCIPAL_INVESTIGATORChevaux Bernard, Dr

Centre Hospitalier Universitaire Vaudois

PRINCIPAL_INVESTIGATORTroxler Stéphanie, PhD Student